MEMPHASYS LIMITED. — Investor Presentation 2012

Nov 29, 2012

==> picture [721 x 136] intentionally omitted <==

Shareholder Update

==> picture [721 x 136] intentionally omitted <==

DISCLAIMER

• This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell NuSep securities or other products should be made only after seeking appropriate financial advice. Reliance should not be placed on information or opinions contained in this presentation and subject only to any legal obligation to do so, the Company does not accept any obligation to correct or update them. This presentation does not take into consideration the investment objectives, financial situation or particular needs of any particular investor.

• To the fullest extent permitted by law, NuSep and its affiliates and their respective officers, directors, employees and agents, accept no responsibility for any information provided in this presentation, including any forward looking information, and disclaim and liability whatsoever (including for negligence) for any loss howsoever arising from any use of this presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this.

==> picture [304 x 181] intentionally omitted <==

==> picture [141 x 66] intentionally omitted <==

NuSep Corporate Structure

==> picture [490 x 182] intentionally omitted <==

==> picture [490 x 182] intentionally omitted <==

==> picture [141 x 66] intentionally omitted <==

New Board Appointments

• Dr Hari Nair will step down as Group Managing Director of NuSep Holdings Ltd and take up the Non Executive Deputy Chairman’s role.

• Mr Prakash Patel will join the Board and will assume the position of Managing Director.

• Mr Clifford Eu will join the Board as a Non Executive Director.

==> picture [141 x 66] intentionally omitted <==

The PrIME Technology

NuSep is the Developer of the PrIME Technology

Current Applications include:

• Plasma Fractionation (PrIME Biologics);

• Sperm Separation (SpermGen).

Future Applications could include:

• Dialysis;

• Recombinant Separations;

• Industrial Enzymes;

• Toxin Removal.

Each new application generates more sales of membranes from NuSep. This is NuSep’s future.

==> picture [141 x 66] intentionally omitted <==

NuSep’s Technology Roadmap

==> picture [680 x 283] intentionally omitted <==

----- Start of picture text -----

High
Therapeutic Division
PrIME Fractionation
$10B Market
SpermSep Clinical Division
$110m Market
Market Potential
ProteoIQ Consumables Division
nUView $200m Market
Low
Technology Shift
----- End of picture text -----

NuSep’s Vision - To be the Premier Technology Supplier in the BioSeparations Market

==> picture [141 x 66] intentionally omitted <==

2011/12

• Full year results to 30[th] June 2012:

• Revenue

• Gross Margin

• EBITDA Loss

• Operational Loss

$2,549,415 Up 42% $1,604,883 Up 44% ($1,128,774) Reduced by 56% ($ 727,843) Reduced by 41%

==> picture [141 x 66] intentionally omitted <==

==> picture [304 x 181] intentionally omitted <==

Consumables

• Consumables Revenue for 30 June 2012 up 47% to $1.8m

• � Focus on key high margin markets US and Europe; with inroads also made into key Asian markets

• Major international Sales & Marketing push by OEM Distributor Thermo Fisher in 2012/13

• NuSep has moved from Direct Sales to Distributor Support

• Focus on Distributor Sales through strong partnership, training and support

• launch of NN Gels now

• Major range, product quality directly comparable with market leader Novex gels

==> picture [140 x 181] intentionally omitted <==

==> picture [141 x 66] intentionally omitted <==

==> picture [166 x 29] intentionally omitted <==

Diagnostics

• NuSep achieved Therapeutic Goods Administration (TGA) accreditation for Diagnostics in November 2012

• NuSep is one of the first IVD manufacturers in Australia to have achieved this accreditation under the recently introduced requirement for ISO 13485 compliance.

• This certification will help NuSep which is now preparing the membrane manufacturing process to supply PrIME Biologics with cartridges to manufacture therapeutic plasma products and SpermGen with IVF cartridges.

• NuSep is in the process of seeking registration of its in-vitro diagnostics products with the European Union (EU) to allow the sale of these products in the EU region. EU registration is expected to be completed in Q1 2013

==> picture [141 x 66] intentionally omitted <==

==> picture [166 x 29] intentionally omitted <==

Distributors-2011/2012

USA

• Thermo Fisher

• BioExpress

• VWR International

• Ward’s Education

Europe

Germany

• PEQLAB Biotechnologie • LTF-Labortechnik GmbH Italy

• Biogenerica S.r.l. United Kingdom

Asia

Hong Kong and China

• Bio-Gene Technology Ltd

Japan

• Takara Bio Inc.

• • Filgen, Inc.

Korea

• Takara Korea Biomedical,

• • Chayon Laboratories, INC

Taiwan

• Li-Tzung Biotechnology,

• • Unimed Healthcare Inc.

• Generon Ltd

Israel

• Tamar Ltd

==> picture [141 x 66] intentionally omitted <==

Thailand

• Pacific Science Co Ltd

==> picture [166 x 29] intentionally omitted <==

SpermSep

• Appointment of New Board to oversee SpermGen developments

• Andrew Goodall is Chair and Professor John Aitken is a board member

• Planning completed for Clinical trial sites

==> picture [140 x 181] intentionally omitted <==

• CROs interviewed with a view of appointment for Clinical trial

==> picture [141 x 66] intentionally omitted <==

==> picture [166 x 29] intentionally omitted <==

Clinical IVF Products Time Line

==> picture [586 x 178] intentionally omitted <==

==> picture [586 x 178] intentionally omitted <==

PrIME Achievements

• Grant from Singapore Government.

• ABS agreement to fractionate CUP.

• Acquisition of Singapore cGMP facility.

• Transfer of Pilot Scale PrIME unit to Singapore.

• Appointment of key regulatory personnel.

==> picture [304 x 181] intentionally omitted <==

• Decision to Spin Out PrIME.

• Future PrIME funding pending.

==> picture [141 x 66] intentionally omitted <==

Therapeutic Plasma Products Time Line

==> picture [557 x 179] intentionally omitted <==

==> picture [557 x 179] intentionally omitted <==

==> picture [141 x 66] intentionally omitted <==

==> picture [183 x 55] intentionally omitted <==

Market Entry Strategy – CUP Market

• Processing the ‘Waste’ or Currently Unprocessable Plasma ( CUP ) allows self sufficiency for regional areas.

• Asian Disposable

• Plasma Low Cost Process Products

• • To Process CUP requires a disposable production method - NuSep’s patented PrIME process is such a process.

==> picture [339 x 69] intentionally omitted <==

----- Start of picture text -----

Disposable
Low Cost
Process Therapeutic
Products
----- End of picture text -----

==> picture [141 x 66] intentionally omitted <==

==> picture [166 x 29] intentionally omitted <==

Market Entry Model and Order book

Model

==> picture [377 x 267] intentionally omitted <==

Order Book – Yearly

Singapore: 10,000 Litres India: 50,000 Litres Revenue: S$32M (A$25M)

==> picture [140 x 181] intentionally omitted <==

Plasma is drawn from India, Processed in Singapore and sold back to India as an Active Ingredient

==> picture [141 x 66] intentionally omitted <==

==> picture [166 x 29] intentionally omitted <==

Dollar Value Comparison of Existin Process vs PrIME g

==> picture [652 x 240] intentionally omitted <==

----- Start of picture text -----

Plasma Plasma Value per Cohn [2] Cohn Cohn $/L PrIME [3] PrIME PrIME $/L Δ g/L 100,000L pa Δ Cohn &
Product Con [1] g protein Yield % Yield % Cohn to PrIME
g/L g/L Yield g/L Yield PrIME [4] Kg $M [5]
Albumin 40g $2.50 25g 65% $62.5 34g 85% $85.0 9g/L 0.9kg $2.25m
IVIG 10g $50.00 4g 40% $200 8g 80% $400 4g/L 0.4kg $20m
Total $52.50 29g $262.50 42g $485.00 13g/L 1.3kg $22.25m
----- End of picture text -----

1. This is the normal concentration of these proteins in a litre of Human Plasma.

2. Cohn fractionation is the technology used by the existing fractionators.

3. PrIME is the disposable manufacturing process used by PrIME Biologics.

4. This column shows the additional protein per gram manufactured using the PrIME process. 5. This column shows the additional profit gained by using the PrIME over the Cohn process.

==> picture [141 x 66] intentionally omitted <==

==> picture [166 x 29] intentionally omitted <==

PrIME Singapore Budget

Budget in S$ Calendar years	2013 S$M	2014 S$M	2015 S$M	2016 S$M	PrIME % to Sales	Existing % to Sales	∆% to Sales
Sales	$0.5	$3.0	$32.7	$49.9
Gross Profit	($0.4)	$0.4	$24.3	$38.1	77%	~50%	+54%
OPEX	($3.7)	($5.5)	($4.7)	($5.4)	11%	~11%	Nil
EBITDA	($4.0)	($3.9)	$20.7	$33.8	67%	~40%	+67%
NPAT	($4.2)	($5)	$17.8	$27.1	54%	~35%	+54%

NPV on the Singapore Project with a 15% Discount is S$69m IRR on the Singapore Project is 55%

==> picture [141 x 66] intentionally omitted <==

PrIME GF100 in situ at the Gemini Facility Singapore

==> picture [461 x 174] intentionally omitted <==

==> picture [461 x 173] intentionally omitted <==

==> picture [141 x 66] intentionally omitted <==